PMID- 32047362
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220412
IS  - 1475-2867 (Print)
IS  - 1475-2867 (Electronic)
IS  - 1475-2867 (Linking)
VI  - 20
DP  - 2020
TI  - The Evi5 oncogene promotes laryngeal cancer cells proliferation by stabilizing 
      c-Myc protein.
PG  - 44
LID - 10.1186/s12935-020-1127-0 [doi]
LID - 44
AB  - BACKGROUND: The Ecotropic viral integration site 5 (Evi5) is recognized as a 
      potential oncogene and a cell cycle regulator. Evi5 regulates the abundance of 
      Emi1, an inhibitor of the anaphase-promoting complex/cyclosome, to govern mitotic 
      fidelity. Evi5 has been shown to be dysregulated in several cancer types. 
      However, the expression and biological function of Evi5 in human laryngeal 
      squamous cell carcinoma (LSCC) are still unknown. METHODS: Clustered regularly 
      interspaced short palindromic repeats (CRISPR)-based gene editing was used to 
      generate Evi5 knockout (KO) LSCC cells. The proliferation and cell cycle 
      distribution of LSCC cells was determined. The effect of Evi5 on LSCC tumor 
      growth in vivo was studied in a tumor xenograft model in mice. The interaction 
      between Evi5 and c-Myc was detected by immunoprecipitation (IP) assay. Luciferase 
      assay was used to determine the transcriptional activity of c-Myc. RESULTS: Here, 
      we show that Evi5 controls LSCC tumorigenesis via the stabilization of c-MYC 
      oncogene. CRISPR-mediated knockout (KO) of Evi5 decreased the proliferation and 
      decreased colony formation ability of LSCC cells. Knockout of Evi5 caused 
      increased G1 phase and decreased S phase cells. In the tumor-bearing nude mice, 
      The transplanted tumors originated from Evi5-KO TU212 cells were significantly 
      decreased when compared with control TU212 cells. At the molecular level, we 
      found that Evi5 interacted with c-MYC and Evi5 antagonized E3 ligase 
      FBXW7-mediated ubiquitination and degradation of c-Myc protein, and promoted 
      c-Myc-dependent transactivation. CONCLUSION: Given the critical role of c-Myc in 
      tumorigenesis, our data suggest that Evi5 is a potential therapeutic target in 
      LSCC, and inhibition of Evi5 should be a prospective strategy for LSCC therapy.
CI  - (c) The Author(s) 2020.
FAU - Mao, Cheng-Gang
AU  - Mao CG
AD  - 1Department of Otolaryngology-Head and Neck Surgery, Jingzhou Central Hospital, 
      The Second Clinical Medical College, Yangtze University, 1 Ren-Min Road, 
      Jingzhou, 434020 People's Republic of China. GRID: grid.410654.2
FAU - Zhou, Xiao-Chun
AU  - Zhou XC
AD  - 1Department of Otolaryngology-Head and Neck Surgery, Jingzhou Central Hospital, 
      The Second Clinical Medical College, Yangtze University, 1 Ren-Min Road, 
      Jingzhou, 434020 People's Republic of China. GRID: grid.410654.2
FAU - Jiang, Yi-Dao
AU  - Jiang YD
AUID- ORCID: 0000-0001-5261-9487
AD  - 1Department of Otolaryngology-Head and Neck Surgery, Jingzhou Central Hospital, 
      The Second Clinical Medical College, Yangtze University, 1 Ren-Min Road, 
      Jingzhou, 434020 People's Republic of China. GRID: grid.410654.2
FAU - Wan, Li-Jia
AU  - Wan LJ
AD  - 1Department of Otolaryngology-Head and Neck Surgery, Jingzhou Central Hospital, 
      The Second Clinical Medical College, Yangtze University, 1 Ren-Min Road, 
      Jingzhou, 434020 People's Republic of China. GRID: grid.410654.2
FAU - Tao, Ze-Zhang
AU  - Tao ZZ
AD  - 2Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan 
      University, Wuhan, 430060 People's Republic of China. ISNI: 0000 0004 1758 2270. 
      GRID: grid.412632.0
FAU - Guo, Jun
AU  - Guo J
AD  - 3Department of Oncology, Affiliated Dongfeng Hospital, Hubei University of 
      Medicine, No. 10, Daling Road, Shiyan, 442008 Hubei People's Republic of China. 
      ISNI: 0000 0004 1799 2448. GRID: grid.443573.2
LA  - eng
PT  - Journal Article
DEP - 20200207
PL  - England
TA  - Cancer Cell Int
JT  - Cancer cell international
JID - 101139795
PMC - PMC7006165
OTO - NOTNLM
OT  - Evi5
OT  - Laryngeal squamous cell carcinoma
OT  - Ubiquitination
OT  - c-Myc
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/02/13 06:00
MHDA- 2020/02/13 06:01
PMCR- 2020/02/07
CRDT- 2020/02/13 06:00
PHST- 2019/11/28 00:00 [received]
PHST- 2020/01/29 00:00 [accepted]
PHST- 2020/02/13 06:00 [entrez]
PHST- 2020/02/13 06:00 [pubmed]
PHST- 2020/02/13 06:01 [medline]
PHST- 2020/02/07 00:00 [pmc-release]
AID - 1127 [pii]
AID - 10.1186/s12935-020-1127-0 [doi]
PST - epublish
SO  - Cancer Cell Int. 2020 Feb 7;20:44. doi: 10.1186/s12935-020-1127-0. eCollection 
      2020.